STERIS Expands Healthcare Consumables Offering with Definitive Agreement to Acquire Xodus Medical, a Specialty Surgical Products Business Focused on Patient and OR Staff Safety

STERIS commits $2.1 billion to acquire Xodus Medical, targeting $245 million revenue in 2026.

What the company is saying

STERIS plc, through its subsidiary STERIS Corporation, has signed a definitive agreement to acquire Xodus Medical, Inc. and related affiliates for $2.1 billion at closing. The company highlights anticipated cash tax benefits with a net present value of $300 million, reducing the net purchase price to $1.8 billion. Management emphasizes that Xodus Medical’s specialty surgical products will expand STERIS’s consumables offering, particularly for operating rooms, and align with its mission of improving patient safety. The announcement frames the acquisition as a strategic fit, citing Xodus Medical’s double-digit growth, new product pipeline, and effective commercial team. CEO Dan Carestio and Xodus Medical CEO Craig Kaforey both stress the cultural and operational alignment, with Kaforey pointing to expanded opportunities for Xodus employees. The deal is expected to be financed primarily with debt and is subject to customary closing conditions and regulatory approvals, with closing anticipated by December 31, 2026. STERIS will update its fiscal 2027 outlook to include Xodus Medical after the transaction closes.

What the data suggests

The acquisition price is $2.1 billion, with anticipated cash tax benefits of $300 million, resulting in a net purchase price of $1.8 billion. There is a potential earnout of up to $150 million contingent on post-closing performance targets in 2028. Xodus Medical’s annual revenue for calendar 2026 is projected at $245 million, with adjusted EBIT of $135 million and projected operating income of $121 million after $14 million in royalty-related charges. All disclosed financial metrics for Xodus Medical are forward-looking, with no historical revenue or profit figures provided. The transaction is to be financed mainly with debt, increasing STERIS’s leverage. The deal structure includes customary adjustments and regulatory approval requirements, with closing targeted for the end of 2026. The company plans to revise its fiscal 2027 outlook post-closing, so the full financial impact on STERIS remains undefined until integration is complete.

Analysis

The announcement is positive in tone and provides detailed figures for the planned acquisition of Xodus Medical, including purchase price, anticipated tax benefits, and projected 2026 financials. However, nearly all key financial metrics (revenue, EBIT, operating income) are forward-looking projections for 2026, not realised results. The transaction is expected to close by December 31, 2026, so benefits will not be immediate. The deal is capital intensive ($2.1 billion, primarily debt-financed), with no immediate earnings impact and only future projections for the acquired business. While the signing of a definitive agreement is a concrete milestone, the narrative inflates the signal by emphasizing anticipated synergies and financial benefits before closing or integration. The data supports that a deal has been signed, but not that any operational or financial improvement has yet been realised.

Risk flags

• ●The acquisition is capital intensive, with a $2.1 billion price tag primarily financed by debt, which will increase STERIS’s leverage and could pressure future cash flows if projected synergies or growth do not materialize. The absence of historical financials for Xodus Medical means investors cannot independently assess the reliability of the $245 million revenue and $135 million adjusted EBIT projections for 2026, raising the risk that actual performance may fall short of expectations.
• ●The transaction is subject to customary closing conditions and regulatory approvals, introducing execution risk that the deal may be delayed or not completed by the targeted December 31, 2026 closing date. Any regulatory or integration setbacks could defer or diminish the anticipated financial benefits.
• ●A potential earnout of up to $150 million is contingent on unspecified post-closing performance targets in 2028, creating uncertainty around the ultimate total consideration and future cash outflows. If Xodus Medical underperforms, the earnout may not be paid, but if targets are exceeded, the acquisition cost could rise.
• ●All disclosed financial metrics for Xodus Medical are forward-looking, with no historical baseline provided, limiting the ability to validate management’s growth claims or assess the sustainability of double-digit growth rates. This reliance on projections increases the risk that actual results may diverge from expectations.
• ●STERIS will not provide an updated fiscal 2027 outlook until after the transaction closes, so investors lack visibility into the pro forma impact on STERIS’s consolidated financials, including potential dilution, integration costs, or synergies.

Bottom line

STERIS is making a major $2.1 billion bet on Xodus Medical to expand its surgical consumables business, with the deal expected to close by year-end 2026 and financed mainly with debt. The company projects $245 million in revenue and $135 million adjusted EBIT for Xodus Medical in 2026, but provides no historical financials, making it difficult to assess the credibility of these targets. The structure includes a $150 million earnout tied to 2028 performance, adding further uncertainty to the total acquisition cost. Regulatory approval and integration remain key hurdles, and the full financial impact on STERIS will not be disclosed until after closing. Investors should focus on whether the deal closes on time, if Xodus Medical delivers on its growth projections, and how the increased leverage affects STERIS’s balance sheet. The most important takeaway is that while the acquisition could be transformative, its success depends on realizing projected growth and managing integration risks.

Announcement summary

(NYSE:STE) STERIS plc announced that its wholly owned subsidiary, STERIS Corporation, has signed a definitive agreement to acquire Xodus Medical, Inc. and certain related affiliates for $2.1 billion at closing. The transaction is expected to generate cash tax benefits with a net present value of approximately $300 million, resulting in a net purchase price of approximately $1.8 billion. The purchase price is subject to customary adjustments, and there is additional potential earnout consideration of up to $150 million based on the achievement of specified post-closing performance targets in calendar 2028. Xodus Medical's annual revenue in calendar 2026 is anticipated to be approximately $245 million, with adjusted EBIT of approximately $135 million. Xodus Medical’s projected operating income for the full calendar year ending December 31, 2026, is $121 million, adjusted for approximately $14 million of charges, substantially consisting of a royalty arrangement that was terminated during 2026. STERIS Corporation will acquire all the equity of Xodus Medical under the terms of the agreement. The transaction is expected to be financed primarily with debt and is anticipated to close by December 31, 2026, subject to customary closing conditions and regulatory approvals. STERIS will provide a revised fiscal 2027 outlook inclusive of Xodus Medical after closing. Dan Carestio, President and Chief Executive Officer of STERIS, stated that Xodus Medical’s product portfolio complements and expands STERIS’s offering, particularly by adding consumables used in the operating room, and aligns with STERIS’s mission to help customers create a healthier and safer world. Craig Kaforey, Chief Executive Officer of Xodus Medical, commented that joining STERIS marks an exciting new chapter for Xodus Medical and provides opportunities for professional growth for its employees. Goldman Sachs & Co. LLC is serving as exclusive financial advisor to STERIS, and Jones Day is serving as legal counsel. J.P. Morgan is serving as exclusive financial advisor to Xodus Medical, and Morgan, Lewis & Bockius LLP is serving as legal counsel.

Disagree with this article?